Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 637490, 2 pages
http://dx.doi.org/10.1155/2008/637490
Editorial

PPARs and RXRs in Male and Female Fertility and Reproduction

Unité de Physiologie de la Reproduction et des Comportements, UMR 6175 INRA-CNRS, Université F. Rabelais de Tours Haras Nationaux, Nouzilly 37380, France

Received 9 December 2007; Accepted 9 December 2007

Copyright © 2008 P. Froment. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear receptors controlling many important physiological processes, including energy homeostasis, lipid, and glucose metabolism, inflammation, as well as cell proliferation and differentiation. PPARs and their heterodimeric partner (retinoid X receptor, RXR) have been found in early embryo, developing fetus, and in various compartments of the reproductive system (hypothalamus, pituitary gland, ovary, uterus, and testis) of many species (birds, fishes, mammals such as rodents, cattle, pigs, and humans) [1]. The reviews in this special issue paint a broad picture of the potential role of the PPAR-RXR system in the reproductive axis. They also raise new questions about the biological actions of the PPAR-RXR system in reproduction and its possible manipulation in treatments of fertility disorders (due to problems with energy metabolism, or specific diseases).

Over the last 10 years, a number of studies in vivo and in vitro have strongly suggested that these nuclear receptors might play an important role from gametogenesis to parturition, including gestation and the links mother/fetus [2]. Thus, PPARs are expressed in the testis where lipid metabolism and specially the β-oxidation of fatty acids are important for testicular functions (steroids synthesis, lipid composition of the sperm, etc.). In addition, some testicular toxicants such as phthalates bind to PPARα and PPARγ and modify their activities. In female, invalidation of PPARγ in the mouse ovary [3] leads to a decrease in fecundity probably due to a drop in the production of sexual steroids. Mice null for PPARβ/δ, PPARγ, or RXRα [46] display alterations in the attachment of embryos to the endometrium and/or placenta development and function. During the labor, mRNA expression of cyclooxygenase-2, an inducer of contractions of the myometrium and a PPAR target gene, is increased in fetal membranes when the PPARα and γ expression drops at the start of parturition. After birth, PPARs continue to play a role in the relation mother/neonates through the mammary gland functions. Indeed, in transgenic mice, a constitutive activation of PPARα in mammary gland alters its development and the lactation leading to mortality of neonates [7]. Furthermore, mice with a deletion of PPARγ in mammary gland produce a “toxic milk” containing elevated levels of inflammatory lipids. Despite these strong phenotypes, the mechanisms of action of these receptors remain unclear in the control of fertility and further investigations are needed to better use them in medical treatments.

In the future, these drugs might also be used in a large spectrum of treatments targeting reproduction such as improvement of follicular development, in vitro fertilization, certain complications of pregnancy, and sex hormone-sensitive cancers affecting the reproductive tissues, including breast, prostate, ovary, or cancers affecting pituitary cells (pituitary adenomas). For example, new generation of pharmacological drugs targeting these receptors are already in clinical use or are undergoing testing for use as therapeutic agents. Synthetic molecules (glitazone molecules, which bind to PPARα, or glitazar molecules, which bind to PPARα/PPARγ), currently being tested in clinical studies, may prove particularly useful for the treatment of certain types of infertility associated with metabolism disorders such as insulinoresistance in polycystic ovary syndrome (PCOS) [8]. The therapeutical treatment in women with pregnancy-specific diseases could be also changed. Women with severe preeclampsia have a reduction in serum levels of PPAR activating lipids several weeks before the onset of symptoms. The use of PPAR ligands might be proposed to ameliorate the disorders associated with preeclampsia such as hypertension and inflammation. Moreover, the rate of success of in vitro fertilization (IVF) could be improved in the next decade by addition in the culture media of PPARβ/δ ligands. Recent studies have shown that the development and implantation of IVF embryos may be augmented by supplementing culture media with PGI2 analogs, a synthetic PPARβ/δ ligand, or retinoic acid [9]. Of note, in all these examples, potential long-term adverse effects are unknown, and more data need to be acquired to consider these drugs “safe” during pregnancy.

Finally, in this issue, we report the putative functions of PPARs and RXRs in gonads, placenta, and embryo and we will discuss the possible role of PPARs as mediators of environmental toxicity for reproductive function.

P. Froment

References

  1. C. M. Komar, “Peroxisome proliferator-activated receptors (PPARs) and ovarian function—implications for regulating steroidogenesis, differentiation, and tissue remodeling,” Reproductive Biology and Endocrinology, 3 pages, 2005. View at Publisher · View at Google Scholar · View at PubMed
  2. P. Froment, F. Gizard, D. Defever, B. Staels, J. Dupont, and P. Monget, “Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition,” Journal of Endocrinology, vol. 189, no. 2, 199 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  3. Y. Cui, K. Miyoshi, E. Claudio et al., “Loss of the peroxisome proliferation-activated receptor gamma (PPARγ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility,” The Journal of Biological Chemistry, vol. 277, no. 20, 17830 pages, 2002. View at Publisher · View at Google Scholar · View at PubMed
  4. Y. Barak, D. Liao, W. He et al., “Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, 303 pages, 2001. View at Publisher · View at Google Scholar · View at PubMed
  5. Y. Barak, M. C. Nelson, E. S. Ong et al., “PPAR γ is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, 585 pages, 1999. View at Publisher · View at Google Scholar
  6. O. Wendling, P. Chambon, and M. Mark, “Retinoid X receptors are essential for early mouse development and placentogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 2, 547 pages, 1999. View at Publisher · View at Google Scholar
  7. Q. Yang, R. Kurotani, A. Yamada, S. Kimura, and F. J. Gonzalez, “Peroxisome proliferator-activated receptor alpha activation during pregnancy severely impairs mammary lobuloalveolar development in mice,” Endocrinology, vol. 147, no. 10, 4772 pages, 2006. View at Google Scholar
  8. P. Froment and P. Touraine, “Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS),” PPAR Research, vol. 2006, Article ID 73986, 8 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  9. J. C. Huang, W. S. Wun, J. S. Goldsby, I. C. Wun, D. Noorhasan, and K. K. Wu, “Stimulation of embryo hatching and implantation by prostacyclin and peroxisome proliferator-activated receptor δ activation: implication in IVF,” Human Reproduction, vol. 22, no. 3, 807 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed